Online inquiry

IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12762MR)

This product GTTS-WQ12762MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets NOTCH1 gene. The antibody can be applied in Lymphoma research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_017617.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4851
UniProt ID P46531
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12762MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ370MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ2014MR IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AGT-181
GTTS-WQ1537MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACE-031
GTTS-WQ7711MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GEXMab73
GTTS-WQ11681MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ6873MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DX-2930
GTTS-WQ9155MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMGN-529
GTTS-WQ1158MR IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABP 215
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW